Browse recruiting and upcoming clinical trials for hypophosphatasia.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this list Hide ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Sex All Female (includes ALL) Male (includes ALL) All sexes only
Age All ages Pediatric (under 18) Adult (18+)
Clear Who can join AI Adults 18–50 years: healthy volunteers and adults with hypophosphatasia (HPP) with a documented ALPL gene variant.
What is being studied AI Tests safety, tolerability, and pharmacokinetics/pharmacodynamics of oral ALE1 in adults, with and without HPP.
Study type Treatment (drug) · Phase 1/2
Countries Germany, New Zealand, United Kingdom
Who can join AI Children and people with symptomatic hypophosphatasia who carry a monoallelic (single) ALPL gene variant.
What is being studied AI Collects clinical, imaging, lab, genetic, functional and patient‑reported data about people with monoallelic ALPL variants.
Who can join AI Adults (age >18) seen in rheumatology with suspected hypophosphatasia and a low ALP test.
What is being studied AI Measures how common hypophosphatasia is in rheumatology patients and develops a diagnostic algorithm.
Who can join AI Adults (age 18+) with hypophosphatasia discovered in adulthood.
What is being studied AI Collects clinical and diagnostic data over time in adults with hypophosphatasia.
Who can join AI People of any age with pediatric-onset hypophosphatasia (first symptoms before age 18) who are receiving or will receive asfotase alfa.
What is being studied AI Collects clinical, lab, antibody, imaging, and quality-of-life data to detect immune-related loss of drug effect.
Who can join AI People with Osteoporosis who were previously treated with the AGN1 LOEP device in the proximal femur between September 2019 and January 2026.
What is being studied AI Collects past safety and performance data after AGN1 LOEP treatment in the proximal femur.
Who can join AI People with a confirmed diagnosis of hypophosphatasia (HPP).
What is being studied AI Collects medical history, clinical data, and long-term outcomes for people with hypophosphatasia.
Who can join AI People with rare or undiagnosed conditions, and unaffected carriers of rare or uncommon diseases.
What is being studied AI Collects patients' contact, demographic, and health information for a centralized rare-disease registry.
Countries Australia, United States
Who can join AI People of any age with a confirmed diagnosis of hypophosphatasia (HPP).
What is being studied AI Collects natural history, symptom and quality-of-life data, epidemiology, and long-term safety/effectiveness in HPP.
Countries Australia, Austria, Canada +9